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Abstract
Background: As every healthcare intervention carries some risk of harm, clinical decision making
needs to be supported by a systematic assessment of the balance of benefit to harm. A systematic
review that considers only the favourable outcomes of an intervention, without also assessing the
adverse effects, can mislead by introducing a bias favouring the intervention.
Much of the current guidance on systematic reviews is directed towards the evaluation of
effectiveness; but this differs in important ways from the methods used in assessing the safety and
tolerability of an intervention. A detailed discussion of why, how and when to include adverse
effects in a systematic review, is required.
Methods: This discussion paper, which presupposes a basic knowledge of systematic review
methodology, was developed by consensus among experienced reviewers, members of the
Adverse Effects Subgroup of The Cochrane Collaboration, and supplemented by a consultation of
content experts in reviews methodology, as well as those working in drug safety.
Results: A logical framework for making decisions in reviews that incorporate adverse effects is
provided. We explore situations where a comprehensive investigation of adverse effects is
warranted and suggest strategies to identify practicable and clinically useful outcomes. The
advantages and disadvantages of including observational and experimental study designs are
reviewed. The consequences of including separate studies for intended and unintended effects are
explained. Detailed advice is given on designing electronic searches for studies with adverse effects
data. Reviewers of adverse effects are given general guidance on the assessment of study bias, data
collection, analysis, presentation and the interpretation of harms in a systematic review.
Conclusion: Readers need to be able to recognize how strategic choices made in the review
process determine what harms are found, and how the findings may affect clinical decisions.
Researchers undertaking a systematic review that incorporates adverse effect data should
understand the rationale for the suggested methods and be able to implement them in their review.
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Background
Systematic reviews are key components in the evidence-
based medicine movement but these reviews have up till
now concentrated on determining the effectiveness of
healthcare interventions. This emphasis on treatment
benefit, together with omission of information on harm-
ful effects, could misinform anyone trying to make bal-
anced treatment decisions. It is now becoming clear that
the harmful effects of interventions should be reviewed
with similar rigour. We therefore believe that it is not
acceptable in the vast majority of instances to systemati-
cally review only the beneficial effects of an intervention.
In the rare case where harms are justifiably excluded, the
reviewers should explain that decision.
Research on 256 systematic reviews of adverse effects has
found substantial uncertainties in the methodology [1].
These problematic areas need to be empirically investi-
gated, but meanwhile a framework is needed to guide
reviewers through this uncertain and evolving area.
The structured approach we present here is based on the
empirical advice given in the Cochrane Handbook for Sys-
tematic Reviews of Interventions. [2] This framework was
developed across meetings and workshops of the Adverse
Effects Subgroup of The Cochrane Collaboration from
2001–2004. The drafting of the manuscript was supple-
mented by a consultation of experts in the methods used
in systematic reviews, as well as those working in drug
safety (listed in the Acknowledgements).
Methods
Formulating the problem: rationale, context, structure, 
scope
Rationale
As with reviews of effectiveness, a clearly focused research
question is essential in a review of adverse effects. Rele-
vant questions will be those that are directly aimed at
guiding the decisions of clinicians, consumers, researchers
and policymakers. A protocol should be developed for the
systematic review and details of the research question
specified, including the types of participants, interven-
tions/exposures, comparisons, outcomes, and study
designs to be included. Selection of outcomes and study
type requires careful consideration in reviews of adverse
effects (See Scope). Systematic reviews which include
adverse effects are likely to make more than one compar-
ison. In that case the early stages of the protocol should
specify what the main comparisons will be and whether
the review will consider both beneficial and adverse
effects. (See 'Using the research question to structure the
review').
Context
A systematic review is time and resource intensive, more
so when it includes adverse effects. The resources devoted
to studying adverse/unintended outcomes should reflect
the importance of the treatment in context. For instance,
if a treatment confers little benefit and is seldom used, its
adverse effects may not be worth detailed evaluation.
Some interventions do require an exhaustive analysis of
all harmful outcomes, but for others adverse effects
require a less thorough investigation. [3] Table 1 describes
some specific therapeutic situations which warrant a
detailed evaluation of adverse effects.
Using the research question to structure the review
Usually, when the focus of the research question is purely
on safety and or tolerability, the effectiveness of the treat-
ment is already known. For example, with MMR (measles,
mumps and rubella vaccination), a review was designed
to look at adverse effects alone. [4] However, in some
instances reviewers intend to evaluate adverse effects as
part of a combined review that also covers beneficial out-
comes. For instance, the mortality-reducing impact of a
new drug for breast cancer may be the main focus of a sys-
tematic review, but there is also a need to weigh up, at the
same time, serious recent concerns about the drug causing
heart failure. Reviews that aim to evaluate benefit and
harm together will usually require a more complex design
that can efficiently handle different sets of studies for var-
ious outcomes. Using different search strategies and/or
eligibility criteria for studies of benefit and harm will gen-
erate two or more diverse groups of eligible studies.
Scope
Selection of adverse outcomes for the review can be diffi-
cult. Unlike reviews of effectiveness, where all beneficial
outcomes are likely to be well recognized beforehand,
specific adverse effects associated with a therapeutic inter-
vention may be known in advance of the review, others
will not. It may not be possible to specify in advance
which effects will be most relevant to the review.
The research question about safety and tolerability in a
review may be broad or narrow in scope. For example, a
review with a broad scope might ask "what adverse effects
are associated with antidepressant therapy in humans?"
Or, a more narrowly focused review might examine the
risk of suicide and suicidal behaviour in adolescents tak-
ing a serotonin reuptake inhibitor. Table 2 describes the
advantages and disadvantages of addressing broad and
narrow questions.
In general, reviewers who have already identified impor-
tant safety concerns (for instance, from the knowledge of
the pharmacology, or anatomical site of the intervention)
should carry out a narrow-focused evaluation coveringBMC Medical Research Methodology 2007, 7:32 http://www.biomedcentral.com/1471-2288/7/32
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particular aspects of the relevant adverse effects. On the
other hand, reviewers who are not aware of any specific
safety problems, could start with a general overview of the
range of adverse effects associated with an intervention. A
widely scoped review may be part of an initial evaluation
which eventually throws up specific safety issues that
merit further focused study.
Such scoping reviews need particular care during the pro-
tocol development. Whilst reviewers carrying out a nar-
row focused review may have to concentrate only on
specific named adverse effects, those performing a broad
review may be confronted with an unstructured mix of
lists, tables and text covering many diverse adverse out-
comes. This difficulty is compounded by the lack of con-
sistency in reporting adverse effects and the absence of a
common format for doing so. Conceptualizing an organ-
izational framework for adverse outcomes at the protocol
stage may help review authors to approach the data in a
systematic, manageable and clinically useful way. A prede-
fined classification of adverse effects, for example, as;
diagnosed by clinician (e.g. gastrointestinal haemor-
rhage), diagnosed by laboratory results (e.g. hypokalae-
mia), or patient-reported symptoms (e.g. pain) will avoid
Table 1: Scenarios where detailed evaluation of adverse effects may decisively influence the decision whether to use an intervention or 
not.
The margin between benefit and harm is narrow Examples:
Treatment is of modest or uncertain benefit, with some possibility of 
harm
• Aspirin for prevention of cardiovascular events in a healthy patient. 
What is the increased risk of haemorrhage from aspirin?
Treatment potentially very beneficial, but there are major safety 
concerns
• Carotid artery surgery in elderly patients with ischaemic heart disease 
who have suffered a stroke. The operation can prevent a future stroke 
but some patients may die from the intervention.
Treatment potentially beneficial in long-term, or to community. No 
immediate direct benefit to individual but possibility of harm exists.
• Improving uptake of a childhood vaccine to promote population 
immunity, while trying to assuage individual parents' fears about early 
serious vaccine- induced neurological damage to their child.
Several effective treatments have differing safety profiles – 
which should be preferred?
Examples:
Treatments are similarly effective, but have different safety profiles • A new insulin injection device is thought to cause less pain than the 
existing device
The balance of benefits and harms differ substantially, e.g. the most 
effective intervention may have serious adverse effects, while the less 
effective one is potentially safer
• Radical mastectomy for breast cancer as opposed to limited, breast-
conserving surgery which is less disfiguring but may carry a greater risk 
of local cancer recurrence.
Adverse effects with an important role in deterring a patient 
from continuing an effective treatment
Examples:
Treatment offers important benefit but adverse effects threaten patient's 
adherence
• The options for a patient with severe heart failure who has responded 
well to an ACE inhibitor, but has persistent cough: stop the medication 
altogether, try a lower dose, or change to an angiotensin receptor 
blocker?
Table 2: Advantages and disadvantages of selecting a broad versus narrow research question for a systematic review of adverse effect
Scope Pros Cons
Narrowly focused, usually evaluating only a 
selected adverse outcome in detail. Example: 
Does antidepressant X increase the risk of 
suicides in teenagers?
Easiest approach, especially with regard to data 
extraction. Hypothesis-testing design allows 
reviews to focus on important adverse effects 
and reach conclusions about treatment 
decision [3]
Conclusions are limited to specific adverse 
effects, and do not provide a complete picture 
of the overall safety or tolerability profile. 
Method is appropriate only for adverse events 
known in advance
Broad sweep. Example: What common 
adverse effects might a patient experience 
when starting on a tricyclic antidepressant?
This method can evaluate new adverse effects 
that were previously unrecognized, and will 
provide a broad general view of potential 
problems. Can also be used as part of a scoping 
exercise to identify specific adverse events that 
merit a further, more detailed look using the 
narrow focused approach.
Danger of being swamped by vast quantities of 
heterogeneous data and of inappropriate 
pooling. Broad, non-specific evaluations can be 
resource-intensive and may yield a diverse 
amount of information from which it is difficult 
to draw any meaningful conclusions. Detection 
of previously unrecognized adverse effects may 
be better addressed through primary 
surveillance than in a systematic review [3]BMC Medical Research Methodology 2007, 7:32 http://www.biomedcentral.com/1471-2288/7/32
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the ad hoc prioritizing of selected adverse effects when
reviewers are confronted with numerous adverse effects at
the data collection stage.
What types of studies?
No single recommendation is possible here, and any deci-
sions have to be made case by case. The decision on what
types of studies to include will depend primarily on the
main focus of the research question, balancing the ele-
ments of type of adverse effects(s) of interest, rigour in
searching, and time and resources available.
Good data on a well-recognized, easily detectable adverse
effect may potentially be available from randomized clin-
ical studies. In contrast, information on new, rare or long-
term adverse effects are unlikely to be found in trial
reports. Trial participants often differ from those given the
intervention in everyday practice. Many RCTs set criteria
which exclude patient groups who are potentially more
likely to be harmed by adverse effects. The systematic eval-
uation of new or rare adverse effects may require the inclu-
sion of other study designs: cohort, case-control, cross-
sectional, and even case series.
On the other hand, authors planning to use such addi-
tional data sources should realise that estimates of the fre-
quencies of adverse effects from published case reports
and spontaneous reporting may differ greatly from the
results obtained from a meta-analysis of double-blind,
randomized controlled trials. [6] A study comparing
adverse outcomes from randomized and non-randomized
studies found that the latter often yield lower estimates of
absolute risk of harm. [7]
Locating and selecting studies
Authors need to develop a literature search strategy based
on key elements in their research question: population,
intervention (plus acceptable comparators), and out-
comes. The review question determines the nature of the
search strategy.
Conducting an adverse effects specific search
The optimal search strategy for specifically identifying
reports of adverse effects has yet to be established. Two
main approaches can be used, each with its own limita-
tions; they are best combined to maximise sensitivity (the
likelihood of not missing studies that might be relevant):
Searching electronic databases using index terms (also called 
controlled vocabulary or thesaurus terms)
Index terms such as MeSH (Medical Subject Headings) in
MEDLINE and EMTREE in EMBASE are assigned to
records in electronic databases to describe the studies.
Subheadings can also be added to index terms to describe
specific aspects – for example, side effects of drugs, or
complications of surgery. Table 3 lists the index terms
used to denote data on adverse effects in the major data-
bases.
Within a database, studies may be indexed in three differ-
ent ways: (i) under the name of the intervention together
with a subheading to denote that adverse effects occurred,
for example, Aspirin/adverse effects, Mastectomy/compli-
cations; (ii) under the adverse event itself, together with
the nature of the intervention, for example, Gastrointesti-
nal Hemorrhage/and Aspirin/, Lymphedema/and sur-
gery/; or (iii) occasionally only under the adverse event,
for example, Hemorrhage/chemically-induced.
Thus, no single index or subheading search term can be
relied on to identify all data on adverse effects, but a com-
bination of index terms and subheadings will help to
detect reports of major adverse effects which the indexers
have considered significant. [8,9]
Searching electronic databases using free-text terms ('text words')
Terms used by authors in the title and abstract of their
studies can be searched on databases of electronic records
using free-text terms. Two problems seriously limit the
value of free-text searching:
Table 3: Indexing terms in MEDLINE and EMBASE
MEDLINE EMBASE
/adverse effects
/poisoning
/toxicity
/chemically induced
/contraindications
/complications
/side effect
/adverse drug reaction
/drug toxicity
/complication
Example:
Aspirin/adverse effects
Here, Aspirin is the MeSH term and adverse effects is the subheading;
Example:
Acetylsalicylic-acid/adverse-drug-reaction
Acetylsalicylic-acid is the EMTREE term and adverse-drug-reaction is the subheading.BMC Medical Research Methodology 2007, 7:32 http://www.biomedcentral.com/1471-2288/7/32
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• authors use a wide range of terms to describe adverse
effects, both in a general sense (toxicity, side-effect,
adverse-effect) and more specifically (eg, lethargy, tired-
ness, malaise may be used synonymously). An author of a
review may not know all these terms in advance but
should try to include as many relevant synonyms as pos-
sible.
• the free-text search does not detect adverse effects not
mentioned in the title or abstract of the study in the elec-
tronic record (even though they appear in the full report)
[9]
A sensitive free-text search should incorporate this poten-
tially wide variety of synonymous terms used to denote
data on adverse effects in studies, while also taking into
account different conventions in spelling and variations
in the endings of terms. So it is necessary to include singu-
lar and plural terms. These terms used to describe adverse
effects should then be combined with free-text terms used
to describe the intervention of interest, for example (aspi-
rin or acetylsalicylic acid) and (adverse or side or hemor-
rhage or haemorrhage or bleed or bleeding or blood loss).
Clearly no single approach will reliably yield all the stud-
ies that have data on adverse effects of an intervention.
The search, therefore, needs to combine index terms and
free-text terms and is likely to take several iterations. For
instance, it may be necessary to repeat the electronic
search incorporating additional index terms, subheadings
and free-text terms derived from initially identified rele-
vant studies. In deciding which combination of terms to
use, authors will need to balance comprehensiveness
(sensitivity) against precision. For example, an electronic
search that retrieves 20,000 studies is likely to contain
most of the relevant studies, but if only 300 (1.5%) are rel-
evant it is very imprecise and resource intensive.
While a more specific and less onerous search can be per-
formed using study design terms such as 'trial' or 'case-
control', the disparate designs of safety evaluations (for
instance, research using 'prescription event monitoring')
and the different terms for describing non-randomized
studies means that reviewers may miss potentially rele-
vant data.
Additional sources of information
Review authors planning an exhaustive search may wish
to consider checking other sources of information on
adverse effects, which include spontaneous reporting sys-
tems and data from regulatory agencies (Appendix B, Sup-
plementary Materials, lists additional sources of
information on harms.)
The value of including data from any of these additional
sources is uncertain. For example, some cases in a sponta-
neous reporting system are inevitably spurious, and
including lists of potentially false harms does not make
the review more useful. While case reports of suspected
adverse reactions are widely published in scientific jour-
nals, few of these reports have been subsequently investi-
gated or confirmed to be valid. [10]
Moreover, a casual user cannot readily apply the detailed
information on harms in large databases. Queries need to
be made in the form of well-designed studies, projects
separate from a systematic review.
Assessing susceptibility to bias
There is often a major trade-off between the comprehen-
siveness and the quality of the adverse effects data
included in a systematic review. Including evidence that is
likely to be biased, even if no better evidence exists, may
lead to biased conclusions. All included data should be
critically discussed and rigorously appraised.
Assessment tools
Many tools exist for assessing methodological quality.
[11] They should identify more rigorous studies with
results closer to the 'truth' – presumably for both thera-
peutic and adverse effects. However, we lack empirical evi-
dence for the relevance of quality tools to adverse effect
analysis. Any available quality assessment tools should be
used cautiously because they may apply only to the pri-
mary focus of the study – usually the beneficial effects of
the intervention. For example, the treatment's benefits
may have been studied in a placebo controlled, well-
blinded, adequately concealed randomized trial, with
standard laboratory measurements. In contrast, the
adverse effects of the same treatment may be collected,
when treatment allocation is known, via a self-assessment
questionnaire completed only by a small proportion of
participants. Although the primary portion of the study
may be of high quality, the monitoring of the harmful
effects of the treatments is not.
One helpful approach may be to categorize the data based
on the study designs included in the analysis. For
instance, reviewers could usefully point out that there was
only small-scale observational evidence for a particular
adverse outcome, while a different adverse effect was
more comprehensively evaluated by specific monitoring
in randomized studies.
General principles
Whatever instruments are selected for assessing bias in
experimental and observational studies of adverse effects
authors should consider two important aspects:BMC Medical Research Methodology 2007, 7:32 http://www.biomedcentral.com/1471-2288/7/32
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• How rigorous were the methods used to detect adverse
effects?
• How good is the reporting?
Examples of potentially useful questions in each area are:
On conduct
Are definitions given of reported adverse effects?
How were adverse effects data collected: prospective/rou-
tine monitoring, spontaneous reporting, patient check-
list/questionnaire/diary; systematic survey of patients?
On reporting
Were any patients excluded from the adverse effects anal-
ysis?
Did the report give numerical data by intervention group?
Which categories of adverse effects do the investigators
report?
Did the investigators report on all important or serious
adverse effects, and how were these defined?
Were the methods used for monitoring adverse effects
reported?
Finally, non-randomized studies are prone to biases,
which can be hard to identify and handle. So far only lim-
ited empirical guidance exists on how to avoid systematic
bias. [12] The Newcastle-Ottawa scale for observational
studies is one example of a tool which has been used in a
few Cochrane reviews to assess potential biases. [13]
Detection methods
The methods used to monitor or detect adverse effects
greatly influence adverse effect frequencies, and may lead
to heterogeneity in systematic reviews. For example, active
surveillance and use of checklists have been shown to
yield substantially higher frequencies of adverse events
than the use of passive or less-focused methods. [14,15]
Studies in which adverse effects are carefully sought will
report a higher frequency than studies in which they are
sought less carefully. Different methods of monitoring
adverse effects yield different results, which may make
comparisons between studies, let alone a formal meta-
analysis, meaningless. [16]
Incomplete reporting
Incomplete reporting of results is also a particular prob-
lem with adverse effects. [17,18] For example:
• Certain categories only may be reported [e.g. the study
states that events were defined by: several body systems,
methods of collection, time periods (3, 6, 12 months),
dose (20 mg, 40 mg, 80 mg), but the authors report only
laboratory results for neurological disorders after 6
months with the 40 mg dose].
• Adverse event categories may not be clearly defined (for
example, 'system = cardiovascular' but without indicating
seriousness, severity, duration, diagnostic method, or
final outcome).
• Treatment groups may be combined (for example, 'x
participants withdrew from the study because of adverse
effects').
• Generic statements (for example, 'no unexpected
adverse effects were seen'/'there was no difference
between the groups in adverse effects reported'/'the drugs
were well tolerated').
In many instances (particularly with the generic state-
ments above), greater account should be taken of what
was left unsaid rather than what was actually reported.
Collecting data
Terms
We suggest that information falling under any of the terms
"adverse effect", "adverse drug reaction", "side effect",
"toxic effect", "adverse event" and "complication" is
potentially suitable for data extraction when evaluating
the harmful effects of a treatment. (See Additional file 1,
Appendix A, Definitions).
Exclusions
Note that no mention of adverse effects does not necessar-
ily mean that no adverse effects occurred. It is usually saf-
est to assume that they were not ascertained or not
recorded: authors must choose whether to exclude the
study from the adverse effect analysis or, exceptionally, to
include it on the assumption that the incidence was zero.
Outcome characteristics
The definition of a particular adverse effect may vary
between studies, as can definitions of severity. Moreover,
a particular adverse effect may be described and/or meas-
ured in different ways among the trials – take for example,
tiredness, fatigue or lethargy, all of which might be terms
used in adverse effects reports. Authors may also use dif-
ferent thresholds for 'abnormal' results (for example,
hypokalaemia diagnosed at a serum potassium concentra-
tion of 3.0 mmol/l or 3.5 mmol/l).BMC Medical Research Methodology 2007, 7:32 http://www.biomedcentral.com/1471-2288/7/32
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Are the adverse effects terms comparable across studies?
Authors will need to decide which categories are similar
enough to be lumped together in the analysis.
A number of initiatives aim to harmonise adverse effects
terms. Examples include the National Cancer Institute
severity grading system [19] and the WHO system-organ
class categories. [20]
Review authors have used the WHO system to collate
adverse effect data into one of several system-organ classes
such as 'gastrointestinal system disorders'. [21] However,
some researchers have found that attempts to shoehorn
an adverse event report into the standard 'preferred terms'
used by regulators and industry can distort descriptions in
the original reports of adverse events and blur distinctions
between them. [22]
Withdrawal or drop-outs as outcome measure
These outcome measures are often seen in trial reports.
Caution is urged when interpreting such data as surrogate
markers for safety or tolerability because of the potential
for bias:
• The attribution of reason(s) for discontinuation is com-
plex and may be due to mild but irritating side effects, seri-
ous toxicity, lack of efficacy, non-medical reasons, or a
combination of causes. [23]
• Patients in trial conditions, and investigators, may have
different thresholds in deciding whether to continue or
end participation in the trial, and this may not reflect the
true experience of adverse events within the general pop-
ulation. For instance, participants who have only limited
access to medical facilities may be favourably disposed
towards the enhanced follow-up they receive in a trial,
and may decide to continue with the intervention, despite
having adverse effects. Investigators who receive incen-
tives based on the numbers of participants completing a
trial may similarly be reluctant to withdraw patients with
adverse effects. In both instances, the converse may also
be true. For example, participants who have good access to
high-quality medical facilities may, in the face of mild
adverse effects, tend to end their trial participation early so
that they can try out other options.
Unblinding of treatment assignment can precede the deci-
sion to withdraw. This can lead to an overestimate of the
intervention's effect on patient withdrawal. For example,
participants in the placebo arm who develop symptoms
may be told that it is unrelated to their trial intervention,
and are thus advised not to drop out. Conversely, patients
in the active intervention group who complained of
symptoms suggesting an adverse effect would be more
readily withdrawn.
Quality of Life indicators
These are usually general measures which do not look spe-
cifically at particular adverse effects of the intervention.
Quality of life scales can be used to gauge overall well-
being, but they cannot be substituted for a detailed evalu-
ation of safety and tolerability.
Analysing and presenting results
If different types of studies are being used to evaluate ben-
eficial and harmful effects, then an author must consider
how to present potentially disparate datasets where stud-
ies reporting intended effects differ from those that report
adverse effects. Special techniques have been devised in
attempts to synthesise data from a diverse range of
sources. [24,25]
The analysis of zero events in either arm (for example,
"the drug was safe", and "no serious adverse effects were
seen") needs careful consideration. Two questions in par-
ticular need to be asked:
• How thorough were the methods used to detect adverse
effects?
• How many patients were studied and for how long?
One cannot conclude from 'zero events detected' that an
intervention does not cause a suspected adverse effect.
However, we can use the rule of three (for sample sizes >
30), to estimate the upper limit of the 95% confidence
interval for the probability of the adverse effect. [26] If no
events were detected in n trial participants, the upper limit
of the 95% confidence interval for the probability of the
adverse event is 3/n. In effect, this gives us a good idea of
what the worst-case scenario could be, if no adverse events
have occurred so far in our sample. If, for example, no
adverse effects occur in 300 participants, then any adverse
effects associated with the intervention might be as fre-
quent as 1 in 100, but are unlikely to be more frequent.
Note that studies with no events in either arm can be
included in a meta-analysis of risk differences, but they
cannot be included in a meta-analysis of odds ratios or
risk ratios.
It is important to remember that a systematic review is not
synonymous with a meta-analysis. In many circumstances
adverse effect information is best summarised in a quali-
tative or descriptive manner. For instance, data derived
from divergent sources cannot be combined because of
different study design, different populations or, different
data collection methods. It may not be possible to com-
pare benefits and harms directly. In practice this means
that adverse effects from RCTs, case reports, case series,
cohorts, and case controls cannot all be pooled together
using standard meta-analysis principles. Further, the dataBMC Medical Research Methodology 2007, 7:32 http://www.biomedcentral.com/1471-2288/7/32
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from non-randomised studies are more prone to bias, and
are often heterogeneous; they should not be combined to
produce a summary statistic if there is important hetero-
geneity.
Analysis and presentation of results categorized by study
design can potentially provide useful insights into a par-
ticular adverse effect. In a systematic review evaluating
pancreatitis with statins, data from case-control studies
were pooled in a meta-analysis to yield a numerical esti-
mate of the relative risk, and to allow assessment of statis-
tical significance. [27] Data from case series and case
reports were then used to identify important characteris-
tics such as patients' age and gender, dose and duration of
drug therapy, and other susceptibility factors involved in
the adverse reaction.
Interpreting results
Applicability
Many RCTs are restricted to selected subgroups of the pop-
ulation, and it is generally inappropriate to extrapolate
adverse effects data from such studies to the wider popu-
lation, which includes more vulnerable people, e.g. those
with co-morbidities, co-medications. In interpreting
adverse effects data, authors must consider the inclusion
and exclusion criteria used in recruiting participants.
Application of any finding to clinical practice will there-
fore always involve a degree of judgement.
Trade-offs
The assessment of benefit versus harm must be considered
in the context of the nature of the condition for which the
intervention is used. For instance, patients with life-
threatening cancer are prepared to tolerate serious adverse
effects from a potentially curative but disfiguring major
surgical procedure. In contrast, patients with a self-limit-
ing illness such as a sore throat may find that the incon-
venience of having antibiotic-induced diarrhoea far
outweighs the uncertain benefit of the drug therapy. These
examples illustrate the need to evaluate the likelihood
and magnitude of benefit and harm together, within con-
text of the particular disease.
Similarly, the quality of evidence may also play a part in
the benefit-harm trade-off. Where a treatment has been
shown in randomized trials to have poor efficacy, even
limited anecdotal evidence of possible adverse effects
might make us decide against the intervention. However,
a cancer patient who opts for a treatment of well-estab-
lished efficacy would probably not be dissuaded by a few
case reports of adverse effects.
Nevertheless, there may be difficulties in assessing the bal-
ance between benefits and harms when the analysis of
harm includes studies beyond those included in the anal-
ysis of benefit. The patient populations used in the benefit
and harm analyses may differ in important ways. Review
authors will need to consider how much, if at all, the par-
ticipants in the additional studies can differ from those in
the benefit studies, and remain comparable.
For example, in a study of the benefits and harms of aspi-
rin used as an antiplatelet drug to reduce cardiovascular
events, a review author might want to include in the
adverse effect analysis a study in which aspirin was used as
an antiplatelet drug to reduce scarring after mastectomy.
Predefined inclusion criteria, other than indication for
treatment (dose, duration of treatment, reporting of
adverse effects), would need to be met. The decision to
include the study or not should depend on whether there
is evidence that these women differ systematically in their
risk of gastrointestinal haemorrhage from people who
take the drug to prevent cardiovascular problems. [28]
Conclusion
Authors are encouraged to recognize that strategic deci-
sions taken in the review process can greatly influence
what harms are found, and so affect future clinical deci-
sions. This guidance document should help authors
explore the consequences of the choices they make in con-
ducting the review, and also to warn of pitfalls. Better con-
ducted and reported studies of harms are certainly
needed; and improvements will help to make systematic
reviews of harms more accurate. [23]
It is also clear that specific methodological research is
urgently needed in those areas where substantial deficien-
cies or uncertainties pose the greatest difficulties for
reviewers. [1]
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